CoChat

MeCP2 modulates gene expression pathways in astrocytes

Open access

The DOI matches its Crossref record; 59 of the 61 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Mutations in MECP2 encoding methyl-CpG-binding protein 2 (MeCP2) cause the X-linked neurodevelopmental disorder Rett syndrome. Rett syndrome patients exhibit neurological symptoms that include irregular breathing, impaired mobility, stereotypic hand movements, and loss of speech. MeCP2 protein epigenetically modulates gene expression through genome-wide binding to methylated CpG dinucleotides. While neurons have the highest level of MeCP2 expression, astrocytes and other cell types also express detectable levels of MeCP2. Recent studies suggest that astrocytes likely control the progression of Rett syndrome. Thus, the object of these studies was to identify gene targets that are affected by loss of MeCP2 binding in astrocytes. METHODS: To identify gene targets of MeCP2 in astrocytes, combined approaches of expression microarray and chromatin immunoprecipitation of MeCP2 followed by sequencing (ChIP-seq) were compared between wild-type and MeCP2-deficient astrocytes. MeCP2 gene targets were compared with genes in the top 10% of MeCP2 binding levels in gene windows either within 2 kb upstream of the transcription start site, or the 'gene body' that extended from transcription start to end site, or 2 kb downstream of the transcription end site. RESULTS: A total of 118 gene transcripts surpassed the highly significant threshold (P < 0.005, fold change > 1.2) in expression microarray analysis from triplicate cultures. The top 10% of genes with the highest levels of MeCP2 binding were identified in two independent ChIP-seq experiments. Together this integrated, genome-wide screen for MeCP2 target genes provided an overlapping list of 19 high-confidence MeCP2-responsive gene transcripts in astrocytes. Validation of candidate target gene transcripts by RT-PCR revealed that expression of Apoc2, Cdon, Csrp and Nrep were consistently responsive to MeCP2 deficiency in astrocytes. CONCLUSIONS: The first MeCP2 ChIP-seq and gene expression microarray analysis in astrocytes reveals a set of potential MeCP2 target genes that may contribute to normal astrocyte signaling, cell division and neuronal support functions, the loss of which may contribute to the Rett syndrome phenotype.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/2040-2392-4-3

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Mecp2 transcripts are below the level of detection in Mecp2/MeCP2-deficient astrocytes. Individual astrocyte samples are shown on the X axis. The Y axis shows the relative microarray signal intensity. In the Affymetrix Mouse 430 2.0 array, Mecp2 is represented by two probe sets, 1460246_at and 1438930_s_at. Both probe sets produced consistent hybridization signals. MeCP2, methyl-CpG-binding protein 2.
Figure 1 Mecp2 transcripts are below the level of detection in Mecp2/MeCP2-deficient astrocytes. Individual astrocyte samples are shown on the X axis. The Y axis shows the relative microarray signal intensity. In the Affymetrix Mouse 430 2.0 array, Mecp2 is represented by two probe sets, 1460246_at and 1438930_s_at. Both probe sets produced consistent hybridization signals. MeCP2, methyl-CpG-binding protein 2.CC BY · PubMed Central
Figure 2 A heat map showing gene expression levels of 119 transcripts including MeCP2 differentially regulated between astrocytes with Mecp2/MeCP2 deficiency and wild-type astrocytes at P < 0.005 and 1.2 fold change threshold. Each column corresponds to individual astrocyte samples (WT: wild-type astrocytes; KO: Mecp2/MeCP2-deficient astrocytes). Each row represents an individual gene. Expression signal intensity was color-coded with red being high and green being low, as shown by the bar to the right. The tree structures to the left and on the top demonstrated similarities between genes and samples, respectively, according to Pearson cluster analysis results. Thus the more similar, the smaller the distance between the tree branches. MeCP2, methyl-CpG-binding protein 2.
Figure 2 A heat map showing gene expression levels of 119 transcripts including MeCP2 differentially regulated between astrocytes with Mecp2/MeCP2 deficiency and wild-type astrocytes at P < 0.005 and 1.2 fold change threshold. Each column corresponds to individual astrocyte samples (WT: wild-type astrocytes; KO: Mecp2/MeCP2-deficient astrocytes). Each row represents an individual gene. Expression signal intensity was color-coded with red being high and green being low, as shown by the bar to the right. The tree structures to the left and on the top demonstrated similarities between genes and samples, respectively, according to Pearson cluster analysis results. Thus the more similar, the smaller the distance between the tree branches. MeCP2, methyl-CpG-binding protein 2.CC BY · PubMed Central
Figure 3 MeCP2 binding is enriched in different regions of modulated genes.(A) Venn diagram comparing the top 10% of MeCP2-bound TSS with genes (large circle) having the highest significance in differential expression (P < 0.005, fold change > 1.2) in MeCP2-deficient astrocytes (small circle). (B) Top 10% of MeCP2-bound gene bodies compared to the MeCP2-responsive transcripts. (C) Top 10% of MeCP2-bound TES compared to MeCP2-responsive transcripts. Zmiz is the only gene transcript to have high levels of MeCP2 binding in more than one region. MeCP2, methyl-CpG-binding protein 2; TES, transcriptional end sites; TTS, transcriptional start sites.
Figure 3 MeCP2 binding is enriched in different regions of modulated genes.(A) Venn diagram comparing the top 10% of MeCP2-bound TSS with genes (large circle) having the highest significance in differential expression (P < 0.005, fold change > 1.2) in MeCP2-deficient astrocytes (small circle). (B) Top 10% of MeCP2-bound gene bodies compared to the MeCP2-responsive transcripts. (C) Top 10% of MeCP2-bound TES compared to MeCP2-responsive transcripts. Zmiz is the only gene transcript to have high levels of MeCP2 binding in more than one region. MeCP2, methyl-CpG-binding protein 2; TES, transcriptional end sites; TTS, transcriptional start sites.CC BY · PubMed Central
Figure 4 Examples of MeCP2 binding enrichment at specific gene regions.(A) MeCP2 binding at the TSS of Aard. (B) MeCP2 binding throughout the gene body of Slc38a1. (C) MeCP2 binding at the TES of Armc3. Cumulative DNA sequences co-purified with MeCP2 from wild-type astrocyte chromatin are depicted as wiggle tracks aligned to the UCSC genome browser NCBI37/mm9 track of the C57BL6/J mouse genome. Read counts are shown on the Y axis. MeCP2, methyl-CpG-binding protein 2; TES, transcriptional end site; TTS, transcriptional start sites.
Figure 4 Examples of MeCP2 binding enrichment at specific gene regions.(A) MeCP2 binding at the TSS of Aard. (B) MeCP2 binding throughout the gene body of Slc38a1. (C) MeCP2 binding at the TES of Armc3. Cumulative DNA sequences co-purified with MeCP2 from wild-type astrocyte chromatin are depicted as wiggle tracks aligned to the UCSC genome browser NCBI37/mm9 track of the C57BL6/J mouse genome. Read counts are shown on the Y axis. MeCP2, methyl-CpG-binding protein 2; TES, transcriptional end site; TTS, transcriptional start sites.CC BY · PubMed Central
Figure 5 Confirmation of MeCP2 ChIP-seq results at selected gene loci.(A) Anti-MeCP2 ChIP (red bar) upstream of the Aard TSS shows significant enrichment compared with a control antibody ChIP (blue bar). (B) Significant enrichment of MeCP2 binding (red bar) in the gene body of Slc38a1 compared to a control ChIP (blue bar). (C) ChIP analysis of Armc3 TES shows significant enrichment of MeCP2 binding (red vs. blue bar). Quantitation of MeCP2 ChIP was performed by real-time PCR using a standard curve where the Y axis represents pictograms of DNA isolated. P values are derived from a one-tailed Student’s t test. ChIP-seq, chromatin immunoprecipitation sequencing; MeCP2, methyl-CpG-binding protein 2; TES, transcriptional end sites; TTS, transcriptional start sites.
Figure 5 Confirmation of MeCP2 ChIP-seq results at selected gene loci.(A) Anti-MeCP2 ChIP (red bar) upstream of the Aard TSS shows significant enrichment compared with a control antibody ChIP (blue bar). (B) Significant enrichment of MeCP2 binding (red bar) in the gene body of Slc38a1 compared to a control ChIP (blue bar). (C) ChIP analysis of Armc3 TES shows significant enrichment of MeCP2 binding (red vs. blue bar). Quantitation of MeCP2 ChIP was performed by real-time PCR using a standard curve where the Y axis represents pictograms of DNA isolated. P values are derived from a one-tailed Student’s t test. ChIP-seq, chromatin immunoprecipitation sequencing; MeCP2, methyl-CpG-binding protein 2; TES, transcriptional end sites; TTS, transcriptional start sites.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 90

Metadata

Authors
Yasui, D. H., Xu, H., Dunaway, K. W., LaSalle, J. M., Jin, L.-W., & Maezawa, I.
Affiliations
  • University of California, Davis (US)
  • National Institutes of Health (US)
  • University of California Davis Medical Center (US)
Corresponding author
Yasui, Dag H
Venue
Molecular Autism
Published
2013
Volume
4
Issue
1
Pages
3
ISSN
2040-2392 (ISSN-L)
OpenAlex
W2151149439
Cited by
90
References
61
Citations by year
2026: 3 · 2025: 4 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 7 · 2020: 4 · 2019: 10 · 2018: 7 · 2017: 7 · 2016: 11 · 2015: 13 · 2014: 9 · 2013: 2
FWCI
7.66
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Molecular Autism (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institutes of Health
  • National Cancer Institute (P30CA093373)
  • National Institute of Neurological Disorders and Stroke (R01NS076263, R01NS081913)
  • National Institute of Environmental Health Sciences (T32ES007059)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD064817)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords
MeCP2, Rett syndrome, astrocytes, epigenetic regulation, gene expression profiling, ChIP-seq, APOC2, CDON, X-linked neurodevelopmental disorder

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MeCP2 modulates gene expression pathways in astrocytes. https://app.cochat.ai/papers/10.1186/2040-2392-4-3
The paper
Yasui, D. H., Xu, H., Dunaway, K. W., LaSalle, J. M., Jin, L.-W., & Maezawa, I. (2013). MeCP2 modulates gene expression pathways in astrocytes. Molecular Autism. https://doi.org/10.1186/2040-2392-4-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.